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Induced Pluripotent Stem Cells (iPSCs) technology has catapulted the field of stem-cell biology through ectopic
expression of reprogramming factors. Ever since its discovery, the potential of iPSCs has been explored by many
scientists to unravel the molecular mechanism responsible for cancer initiation and progression. Besides modeling
cancer, the further applications of this technology includes high-throughput drug screening, epigenetic reprogramming
of cancer cell state to normal, immunotherapy and regenerative cell therapies. Here, we review the current challenges on
clinical applications of iPSCs with respect to understanding cancer and personalizing treatment for the disease.
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Brief history of pluripotency
Reprogramming somatic cells has a long history back in the
year 1966 when adult frog was developed by nuclear trans-
plantation of differentiated somatic cell nuclei. Initially, this
finding was heavily criticized but got validated later and
generated many speculations regarding the totipotency
nature of differentiated adult nuclei [1]. After success of
nuclear transfer technology in frog, various animal models
including sheep which has resulted in the generation of
Dolly from cells derived from the adult mammary glands
[2]. The birth of viable lamb has reinforced the previous
speculations that the molecular clock of differentiated cells
can be reverse back to the embryonic stage and they still
retain the epigenetic memory of embryonic development.
However, cloning suffered a number of disadvantages
because of the inefficiency of technique and the dangerous
impact it has on the individual clones. The discovery of
human embryonic stem cells (hESCs) in the year 1998 has
revolutionized the field of stem cells and regenerative medi-
cine because of the remarkable potential of hESCs to differ-
entiate into any cell types of the body [3]. Nevertheless, the
use of hESCs poses many ethical and immunogenic issues.* Correspondence: ppotdar@jaslokhospital.net; ppravin012@gmail.com;
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and Yamanaka reported the reprogramming of murine
fibroblast by ectopic expression of Oct4, Sox2, Klf4 and
c-Myc [4]. Similar finding was translated to human dermal
fibroblasts by two independent research group in 2007
[5, 6]. These cells referred to as induced pluripotent stem
cells (iPSCs) exhibit similar morphological, proliferative,
genomic and phenotypic characteristics as hESCs as well
as express analogous cell surface antigens.
Ever since the discovery of iPSCs, it has ushered a new
era of personalizing pluripotency genes excluding the
involvement of ethical concern while simultaneously
addressing the issue of transplantation without the fear
of graft rejection. Scientists have started to generate
patient-specific iPSCs to unravel the molecular mechan-
ism responsible for Fanconi anemia [7], diabetes [8] and
Wilson’s disease [9]. The only drawback of this technology
for its use in personalized medicine is the risk associated
with the use of lentiviral or retroviral vectors resulting in
genomic integration and insertion mutagenesis [10]. In
addition, generation of iPSCs is limited due to lower re-
programming efficiency [1] and the longer duration it
takes for reprogramming (several weeks) [11]. To over-
come viral vector mediated genotoxicity, reprogramming
methods have been refined progressively to deliver pro-
gramming factors either by using non-integrating viruses
[12, 13], episomal vectors [14] and direct delivery ofle is distributed under the terms of the Creative Commons Attribution 4.0
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as valproic acid have been substituted for the oncogene
c-Myc and it has been shown to increase the repro-
gramming efficiency by 100-fold [16]. Another approach
to improve reprogramming efficiency is by expressing co-
factors such as BAF(Brg1/Brm associated factor)- complex
that modulates the de-methylation status of pluripotency
gene promoters [17, 18]. However, in spite of all the ef-
forts towards increasing the reprogramming efficiency
there is still a deficit in establishing the optimal repro-
gramming protocol.
How iPSCs can help to cure cancer?
Even though we are living in the post-genomic era, there
are still many questions in the field of cancer biologyFig. 1 Applications of iPSCs in cancer therapy. Induced pluripotent stem ce
NK cells which on adoptive transfer into patient launch an attack on tumo
reprogramming of cancer cells which could be used both as a therapy for
screening. Additionally, gene editing technology could also be used to cor
types and could be used for further transplantation purposethat need to be answered. The foremost question is what
makes a cancer cell a cancer cell? Are we even closer to
eradicate cancer completely? Treating cancer is still one
of the most daunting tasks of 21st century despite of all
the scientific advances in cancer treatment over the past
30 years. Out of all the types, metastatic cancer remain
the most challenging one as there are very few thera-
peutic options and majority of the patient show severe
side-effects resulting in mortality because of the treat-
ment itself. But how can the potential of iPSCs be har-
ness to treat cancer patients? There are four possible
scenarios where iPSCs might be of value as shown in
Fig. 1: i) modeling cancer pathogenesis & drug screening
ii) reprogramming cancer cells back to normal phenotype
iii) cancer immunotherapy iv) regenerative cell therapies.lls derived from cancer cells can be differentiate into T cells, DC and
r; these iPSCs can also be exploited to understand the epigenetic
cancer and as model to study cancer pathogenesis including drug
rect cancer mutation in iPSCs which could be differentiate into any cell
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cancer-specific iPSCs
The molecular mechanism responsible for malignant trans-
formation is still not clearly understood to many scientists
and conducting such analysis in patient samples does not
represent a perfect model because the transformation event
has already occurred when cancers are studied. Therefore,
there is a big lag in data to unravel the early stages of
cancer progression because of the inadequate system to
recapitulate the cancer phenotype. Moreover cancer-specific
mutations, deletions, translocations are usually associated to
particular tissue type which indicates that the effect of these
mutations are not only influenced by the environmental
triggers but also heavily dictated by the epigenetic states of a
cell [19] Therefore, iPSCs provide a platform to understand
the association of oncogenic mutations with different tissue
types and how these mutations dictate the malignant fate of
the cell.
For instance, pancreatic ductal adenocarcinoma (PDAC)-
derived iPSCs demonstrate the in vitro model system to de-
velop pancreatic intraepithelial neoplasia which can further
progressed to pancreatic cancer. By using immunodeficient
mice, Kim’s group has shown that PDAC-derived iPSCs
when injected into the mice, they generated progenitors of
PDAC referred to as pancreatic intraepithelial neoplasia
(PanIN). This PanIN later progress to the metastatic stage
and further profiling of PanIN reveals the network of many
proteins centered on the gene HNF4a. This gene was not
previously implicated in PDAC and therefore provides new
insights into pancreatic cancer progression [20]. Thus,
iPSCs proves to be a valuable tool in capturing the early
stage of cancer progression. Li Fraumeni syndrome (LFS)
which is caused due to the mutation in the p53 gene has
been successfully modeled by using iPSCs technology [21].
Initially it was difficult to understand the molecular patho-
genesis of this disease because LFS patients suffers from
wide spectrum of cancers and the mouse model of LFS
could only provide the one-dimensional information on the
disease. LFS patient-derived iPSCs recapitulated all the hall-
marks of the disease and thus establishing as a stand-alone
model system for familial cancer covering all the extreme
ends of cancer spectrum.
In addition, large-throughput drug screening and devel-
opment can be assayed by reprogramming cancer-cell-
specific iPSCs into the cell type of the interest. The ration-
ale behind this approach is to screen for various panel of
drugs that specifically kill cells carrying oncogenic muta-
tions. Since chemotherapy drugs have undesirable side
effects,, cytoxicity drugs screening assays need to be de-
veloped that selectively target mainly cancer cells and
have minimized side-effects. In one of the case report
published by Moriguchi and Mandane, they have suc-
cessfully generated patient-specific hepatoma-like cells
(HLCs) derived from the iPSCs of the patient sufferingfrom hepatocellular carcinoma (HCC) [22]. They later
performed the in vitro anticancer drug sensitivity assay
on HLCs using acyclic retinoid (ACR) plus tolrestat as
an aldo-ketoreducatse family 1, member 10 (AKR1B10)
inhibitor. As a result of the drug treatment, the patient
cancer cells were eliminated six days later in vitro. Based
on this drug sensitivity results, the patient was treated
with ACR plus tolrestat therapy and his HCC was disap-
peared in three months [23]. This study provided the
proof-of-concept for the development of drug treatment
using the iPSCs technology.
Can we reprogram human primary cancer cells? -the big
paradox
Similar to non-cancerous cells, many attempts has been
made to reprogram human primary cancer cell lines to
pluripotency. Despite all the efforts, it has proven that
reprogramming primary human cancer cell lines is inef-
ficient and hence called the ‘paradox’. Although technical
constraint is one of the potential reasons for failure, there
is compelling evidence of biological hurdles as another
barrier. Hochelinger et.al 2004 have shown that blasto-
cytes cloned from RAS- induced melanpoma nuclei give
rise to Embryonic Cell (EC) which can differentiate into
malonocytes, Lymphocytes and fibroblasts. However this
reprograming was not possible by nuclei of Lekemia,
Lymohoma or breast cancer cells to produce EC cells
[24]. Alternatively, cancer-specific genetic mutations, DNA
damage, epigenetic modifications and oncogene-induced
senescence also impose the additional hurdles in repro-
gramming but they do not represent an insurmountable
one, a topic that has been reviewed in great detail else-
where [25].
Despite all the hurdles, several researchers have pub-
lished the generation of novel iPSCs from cancer cell
lines. Carette et.al 2010 have demonstrated succesfully
the generation and characterization of iPSCs derived
from human chronic myeloid leukemia cells by transfect-
ing 4 sets of transcriptional factors such as Oct4, SOX2,
cMyc & Klf4. Interestingly, it was observed that the paren-
tal cell line was strictly dependent on the BCR-ABL sig-
naling, however, reprogrammed cells lost this dependency
and became resistant to the BCR-ABL inhibitor imatinib.
This finding thus indicated that the therapeutic agent ima-
tinib targets cells in a specific epigenetic differentiated cell
state and this may contribute to its inability to fully eradi-
cate disease in chronic myeloid leukemia patients [26]. In
another study published by Choi et.al 2011 have used
EBV-immortalized B lymphocyte cell lines which repre-
sent an important source of genetic information from pa-
tients of various diseases including cancer. These EBV-B
cells can be excellent resource for generation of diseases
specific iPSCs & can be used for various human diseases.
Choi et al. have successfully reprogramed these EBV- B
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generated by this method retained the inherited diseases
properties [27]. Finally, the most interesting work on
cancer cell reprogramming came from Hu’s laboratory.
Because of limited genetic abnormalities in hematopoietic
cells in many blood diseases, several studies have dem-
onstrated successful reprogramming of Cord Blood &
peripheral blood cells to generation of iPSCs cells and
thus this is become a successful iPSC-based models for
hematologic diseases. However, there are limitations of
current reprogramming technologies include low effi-
ciency, slow kinetics, transgene integration and residual
expression. Hu et. al 2011 have overcome these limita-
tions & demonstrated the generation of iPSCs from BM
& CB mononuclear cells which was free of transgene
and vector sequences using non-integrating episomal
vectors. The reprogramming was up to 100 times more
efficient, occurs within 1-3 weeks faster as compared
with the reprogramming of fibroblasts, and does not re-
quire isolation of progenitors or multiple rounds of
transfection. They have also generated iPSCs from BM
of a patient with chronic myeloid leukemia (CML) and
showed a unique complex chromosomal translocation
identified in marrow sample while displaying typical
embryonic stem cell phenotype and pluripotent differenti-
ation potential. This approach provides an opportunity to
explore normal and diseased CB and BM samples without
the limitations associated with virus-based methods [28]
The scarcity in the report of reprogramming cancer cells
has hampered the cancer research in dissecting all the
additional factors imposing hurdles on successful repro-
gramming. Scientists working in oncology, stem cells and
regenerative medicine should be persuaded to publish
negative data which might provide specific clues to define
these hurdles.
Reversing the ‘cancer state’ to normal through epigenetic
reprogramming
A corollary to the reprogramming of cancer cells is that
if they can be reversed to pluripotent state, it would sug-
gest that the chromatin remodeling of oncogenes and
tumor suppressor genes might results in reversing the
‘cancer state’. However, it is also possible that chromatin
modeling controlling the reprogramming process can
also drives the ‘cancer state’ if subjected to aberrant
regulation [29]. Thus, reprogramming, pluripotency and
malignant transformation are connected processes that
are dictated by epigenetics [28] For instance, in trans-
formed lung fibroblast, epigenetic silencing of tumor sup-
pressor gene p16 (CDKN2A) was reported to be a ‘cancer
driven’ mechanism. However, reprogramming successfully
restored the p16 gene expression and it was also associated
with erasing of epigenetic lesions associated with cancer -
[23]. In another study published by Zhang and coworker,they have demonstrated that direct nuclear reprogramming
of sarcoma cells not only abrogates their tumorigenicity
but also reduce drug resistance. Further DNA methylation
profiling on reprogrammed sarcoma cells indicated the
permissive change in chromatic structure for methyl
writers (c-Myc silencing) [30]. These findings suggest that
the aggressiveness of cancer reduced after reprogramming
and hence can be used as a potential therapy for cancer.
However, there are other studies which showed totally
contradicting results on the oncogenic state of cancer
cells after reprogramming. Exogenous expression of Oct4
in human primary breast cells results in transformation of
cells with overexpressed telomerase and down-regulated
p16. Further injection of these transformed cells in nude
mice generated breast carcinomas with metastatic poten-
tial [31]. In another recent study, co-expression of both
Oct4/Nanog enhanced malignancy in lung adenocar-
cinoma and induces epithelial-mesenchymal transition
(EMT). Thus, both studies independently established
the notion that these pluripotency genes if expressed
aberrantly could become oncogenic driver imparting
self-renewal capability to cancer cells - [32]. Therefore,
before bringing reprograming of cancer cells by pluri-
potency genes as a one of the cancer therapy from
bench to bedside, further investigation is still required
regarding the optimum levels of reprogramming factors
that should be expressed in the cancer cells in order to re-
verse the malignant phenotype. Nevertheless, the future is
still looking bright for cancer cell reprogramming as a
therapy due to the recent groundbreaking discovery by
Mayo Clinic on reversing cancer cells back to normal
through epigenetic remodeling [33]. In this study,
Kourtidis et.al 2015 have highlighted the roles of E-cadherin
and p120 catenin (p120) in exerting pro-tumorigenic
activities of these proteins by balancing epithelial homeo-
stasis in normal cells. They have resolved this hypothesis
by identifying two spatially and functionally distinct junc-
tional complexes in normal epithelial cells. They have
straightened out the complicated roles of E-cadherin and
p120 in the context of distinct junctional complexes, sep-
arating their functions. In addition, they have identified
PLEKHA7 as a specific marker of zonula adherens (ZA)
that facilitates suppression of growth of transformed cells.
Finally, they discovered that an interaction of the ZA with
the microprocessor complex regulates a set of miRNAs to
suppress cellular transformation and maintain the normal
epithelial phenotype [33].
IPSCs in cancer immunotherapy
Immunotherapy is the holy grail for cancer treatment
and it involves generation of tumor specific-immune
cells which on adoptive transfer elicit cytotoxic response
against tumor. It has already been applied in clinical
settings but due to the shorter life span of activated
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the effect is not substantial to cure patient [34]. To ad-
dress this issue, the iPSCs technology could provide the
platform to clone and expand tumor-specific T cells.
Lei and coworkers have demonstrated for the first time
that iPSCs could differentiate into T lymphocytes when
co-cultured with OP9 cells. They have further reported
that iPSCs-derived T cells could be successfully utilized
for adoptive immunotherapy using Rag-deficient mice
model - [35]. Another interesting study by Japanese re-
searchers has provided an approach to generate and ex-
pand functional tumor antigen-specific CD8+ T cells.
They have induced MART-1 antigen specific T cells
into iPSCs and successfully generated large pool of
MART-1 specific CD8+ T cells. The ex vivo generated
T lymphocytes were functionally active and produced
anti-tumor compound interferon-γ when stimulated with
MART-1 antigen [36]. The next critical step is to see
whether these regenerated T cells can selectively kill
tumor cells in vitro and in vivo. In addition, such studies
should be conducted with discretion since one of the
reports has shown that iPSCs derived from various cell
types exhibit different gene expression profile and has
an influence on the differentiation potential. However,
these differences were weakened by continuous passa-
ging of iPSCs cells [37].
Natural killer cells, another player of innate immune
system also play an important role in generating anti-
tumor response by secreting Th1 cytokines [38]. How-
ever, the only hurdle in the application of NK cells for
immunotherapy is to get the sufficient number of cells
which can be infused in patient. Woll et al.for the first
time developed a method to differentiate human ES cells
into functional NK cells in vitro [39]. Subsequently,
using the similar culture system, NK cells were also suc-
cessfully differentiated from human iPS cells. Import-
antly, these iPSCs-derived NK cells had the potential to
actively suppress human tumor cells and they produced
high levels of interferon-γ [40]. In a recent study, it has
been shown that NKT cells could also be derived from
iPS cells. These cells play an important role in cancer
immune surveillance as they share the properties of both
NK and T cells [41].
Dendritic cells (DCs) are the most potent antigen-
presenting cells and contribute strongly towards regulat-
ing the immune system by constitutively synthesizing
high levels of MHC Class I/Class II molecules. For de-
cades, DCs have been used to induce robust therapeutic
immune modulation in a highly effective manner [42]
Loading of DCs with tumor-specific antigens followed
by reinfusion into the recipient organisms generated
promising results both in mice [43] as well as in human
trials [44]. The other advantages of using DCs is they
can be genetically manipulated easily using viral genedelivery vectors, have shorter life-span and they don’t
proliferate indefinitely as in the case of gene modified T
cells which sometimes result in lymphoma [45]. Despite
the promising results, isolation and in vitro propagation
of DCs still represents the most challenging task which
also increases the overall costs. This therapeutic limita-
tion of DCs can be overcome by using iPSCs-derived
DCs and hence represents the renewable source to broaden
the immunotherapeutic applications [46]. Silk et al. have
successfully generated CD141+XCR1+DCs from iPSCs
using combination of stem cell factor (SCF), granulo-
cyte macrophage-colony stimulating factor (GM-CSF),
bone morphogenetic protein-4 (BMP4) and vascular
endothelial growth factor (VEGF) without the usage of
animal products. These iPSCs-derived DCs efficiently
processed the recombinant TAA, Melan A antigens and
cross-presented to naïve CD8+ T cells resulting in im-
mune response [47]. Thus, considering all the immense
potential of iPSCs in the field of immunotherapy, we
are definitely not far from the days when we can look
back on chemotherapy and radiotherapy as barbaric
way of treating cancer.
Gene correction in iPSCs and autologous transplantation:
precision medicine
Molecular scissors such as zinc finger nucleases (ZFN),
transcription activator like-effector nuclease (TALEN)
and clustered regularly interspaced short palindromic re-
peats (CRISPR) have emerged as the powerful gene edit-
ing tools to conduct precise-genome editing including
the correction of disease-associated mutations [48–50].
Zinc finger nucleases (ZFNs) are synthetic DNA-binding
proteins which facilitate genome editing by creating a
double-stranded break by cleaving domain of the FokI
restriction endonuclease in DNA at a user-specified
location. This double-stranded break stimulates the
cell’s natural DNA-repair processes and thus by using
well-established protocols, these cellular processes can
be harnessed to generate precisely targeted in vitro or
in vivo genomic edits with targeted gene deletions
(Knockouts), integrations, or modifications. ZFNs are
broadly applicable and accessible molecular tools for
performing targeted genetic alterations [48]. Whereas,
Transcription Activator-like Effector Nucleases (TALENs)
works on the same principle as ZFNs. TALENs are fusions
of transcription activator-like (TAL) proteins and a FokI
nuclease. TAL proteins are composed of 33-34 amino acid
repeating motifs with two variable positions that have a
strong recognition for specific nucleotides. By assembling
arrays of these TALs and fusing them to a FokI nuclease,
specific cutting of the genome can be achieved. When
two TALENs bind and meet, the FokI domains induce a
double-strand break which can inactivate a gene, or can
be used to insert DNA of interest. TALENs are more
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problem that faced by ZFN researchers [49]. The third
newly developed gene editing technology is the Clus-
tered, Regularly Interspaced, Short Palindromic Repeat
(CRISPR) technology which generates RNA-guided nu-
cleases, such as Cas9, with customizable specificities.
Genome editing mediated by these nucleases has been
used to modify endogenous genes in a wide variety of
cell types. These systems will influence to perform tar-
geted & highly efficient alterations of genome sequence
and will certainly alter biological research program to-
wards development of novel molecular therapeutics for
human disease [50]. But how these genome editing
tools could be utilized in the field of iPSCs in context
to treat cancer? Most of the cancers are caused due to
a mutation in a specific gene; the mutated gene of pa-
tient cells can be corrected through genome editing
tools. The corrected cells of patient can be converted
into iPSCs and differentiate them into specific-lineage
of cells which could be used further in autologous
transplantation approach as a therapy in future [51].
For instance, mammary gland is the primary target of
breast cancer caused by the mutations in the BRCA1/
BRCA2 genes [52] Treatment for breast cancer usually
involves a combination of radiotherapy and chemotherapy
which often results in damaging the mammary glands.
The only way to restore the function of mammary gland is
simply by regenerating the damaged gland. Li et al., have
successfully developed iPSCs from mouse mammary
epithelial cells (ME-iPSCs) and re-differentiated them
back into mammary epithelial cells (D-ME-iPSCs). Fur-
ther transplantation of these D-ME-iPSCs into the fat
pads of the mammary glands of nude mice result in the
generation of mammary tree-like structures in vivo [53]
Thus, this study envisions the use of iPSCs-derived tis-
sue which could be used in parallel with gene editing
tools to generate genetically corrected BRCA1/BRCA2
mammary cells. Besides, this gene editing platform has
been successfully utilized to correct gene defect in
iPSCs-derived from severe combined immunodeficiency
(SCID) [53] and fanconi aneamia patient (hematological
diseases) [54].
However, there are current limitations to the use of
gene editing tools to precisely delete or modify cancer
genes in patient as a therapy. The efficiency of gene tar-
geting in iPSCs using homologous recombination is very
low [55]. and the use of viral vectors for gene modifica-
tions causes insertional mutagenesis which represents
the most significant hurdle in clinical translation [10].
Despite the fact that bone marrow transplantation is a
routine medical procedure, there is still no sign of clin-
ical translation on gene corrected iPSCs. The other miss-
ing link seems to be the development of novel protocol
for the generation of iPSCs-derived transplantable cellswhich could result in successful engraftment in the host.
A deeper understanding in the biology of organs develop-
ment, pre-clinical studies in various animal models and
the development of viral free high efficient gene targeting
technology are needed to address all the hurdles.
Conclusions
Induced pluripotent stem cells have ushered a new era
in the field of cancer biology and are the most promising
technology to conduit between the bench and bedside.
Some scientists have called it as the ‘holy grail’ of 21st
century. Since it is possible to develop patient specific
iPSCs from somatic tissues, this contributes in modeling
diseases, drug development and autologous stem cells
therapy. In the field of cancer, iPSCs has provided a
double-edge sword that enable scientist not only to un-
ravel the long mystery of epigenetic events contributing
to cancer but also a renewable resource to develop
plethora of immune cells for immunotherapy. By using
the recent gene editing tools, it is also possible to correct
the genetic defect in patient-specific iPSCs which could
be used in autologous transplantation. The ample amount
of knowledge that can be generated from this technology
will leads to better drug screening that will have more
targeted effect and less toxicity. Thus, the iPSCs tech-
nology will definitely accelerate the field of scientific re-
search in finding new treatment for treating cancer and
other disorders.
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